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Expression of complement and toll-like 
receptor pathway genes is associated 
with malaria severity in Mali: a pilot case control 
study
Rafal S. Sobota1,2†, Antoine Dara3,4†, Jessica E. Manning5†, Amadou Niangaly3, Jason A. Bailey4, 
Abdoulaye K. Kone3, Mahamadou A. Thera3, Abdoulaye A. Djimdé3, Guy Vernet6, Philippe Leissner7, 
Scott M. Williams2, Christopher V. Plowe4* and Ogobara K. Doumbo3
Abstract 
Background: The host response to infection by Plasmodium falciparum, the parasite most often responsible for 
severe malaria, ranges from asymptomatic parasitaemia to death. The clinical trajectory of malaria is influenced by 
host genetics and parasite load, but the factors determining why some infections produce uncomplicated malaria 
and some proceed to severe disease remain incompletely understood.
Methods: To identify molecular markers of severe falciparum malaria, human gene expression patterns were 
compared between children aged 6 months to 5 years with severe and uncomplicated malaria who were enrolled 
in a case–control study in Bandiagara, Mali. Microarrays were used to obtain expression data on severe cases and 
uncomplicated controls at the time of acute disease presentation (five uncomplicated and five severe), 1 week after 
presentation (three uncomplicated and three severe) and treatment initiation, and in the subsequent dry season (late 
convalescence, four uncomplicated and four severe). This is a pilot study for the first use of microarray technology in 
Mali.
Results: Complement and toll-like receptor (TLR) pathways were differentially expressed, with severe cases showing 
higher expression of the C1q, TLR2, TLR4, TLR8, and CR1 genes. Other genes previously associated with malaria patho-
genesis, GZMB, FOS and HSPA6, were also higher among severe cases. TLR2, TLR4, TLR8, CR1, GZMB, FOS, and HSPA6 
genes were expressed at lower levels in severe cases at late convalescence.
Conclusions: Overexpression of genes previously associated with uncomplicated malaria was associated with severe 
disease. Low baseline expression of these genes may represent candidate markers for severe malaria. Despite the 
small sample size, results of this pilot study offer promising targets for follow-up analyses.
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Background
Malaria continues to be a significant cause of morbid-
ity and mortality with an estimated 438,000 deaths and 
214 million cases in 2015 [1]. The response to infection 
by Plasmodium falciparum, the parasite responsible 
for most severe malaria, is varied and complex, ranging 
from asymptomatic parasitaemia to death. It has been 
estimated that out of 400 people who are bitten by P. 
falciparum infected Anopheles mosquitoes, 200 will be 
infected, 100 will develop the uncomplicated form of the 
disease, two will develop severe symptoms, and one will 
die [2]. Numerous factors affect the clinical manifestation 
of malaria, including a patient’s age [3], level of P. falci-
parum transmission [4], parasite virulence [5], and gene 
expression levels in both the host and the parasite [6, 
7], among others [8]. Uncomplicated malaria is typically 
defined by fever accompanied by a blood smear positive 
for asexual P. falciparum. Severe malaria manifestations 
include severe anaemia, hypoglycaemia, acidosis, neuro-
logical symptoms from cerebral involvement, end-organ 
damage and/or respiratory distress [9]. The biological 
bases for differences in clinical manifestations remain 
largely unexplained.
Selective pressure of P. falciparum on human evolu-
tion has helped to shape the human genome; in addition, 
the P. falciparum and human genomes have co-evolved 
because sub-clinical infection or uncomplicated disease 
is more advantageous to the parasite than severe disease 
[10]. Examples of selection on the host genome include 
sickle cell trait (HbS), thalassaemias, haemoglobin C, and 
other erythrocyte variants [11]. These variants have been 
argued to play a more prominent role than environmental 
factors in the outcome of malaria infection [12]. Despite 
the importance attributed to genetically determined host 
responses, relatively few genetic variants have been iden-
tified that affect the clinical trajectory of infection. This 
is highlighted by the observation that sickle cell trait, 
the most prominent protective genetic mechanism, only 
explains 2 % of the total variation in response to P. falci-
parum infection [11]. To address this, analyses of human 
genomic variation using genome-wide level data have 
been performed to identify additional factors [13], but 
because of linkage disequilibrium patterns in Africans, 
such genome-wide analyses are problematic [14]. Alter-
native approaches that specifically target human genes in 
toto may be more fruitful. One technically feasible design 
is to assess genome-wide levels of expression to gauge the 
most important genes in response to infection.
Few studies to date have used microarray technology 
to identify host genes involved in response to P. falcipa-
rum infection. One study demonstrated a possible role 
for up-regulation of neutrophil and erythrocytic activ-
ity in 22 Kenyan children with fever and P. falciparum 
parasitaemia or other acute febrile illnesses [15]. In 
another study, toll-like receptors were shown to be 
induced by malarial infection irrespective of prior expo-
sure, demonstrating the same pattern of expression in 22 
experimentally infected, naïve volunteers in the USA and 
22 naturally infected Cameroonians [16]. Although gen-
erally informative regarding innate and humoral immu-
nity at a single time point, these studies provide data on 
temporally static measures against varied ethnic back-
grounds, or only consider P. falciparum infection as a sin-
gle clinical entity. Both of these factors may be critical in 
evaluating the results of expression studies.
To address the possible complicating factors of both 
the temporal differences in gene expression and host 
genetic diversity, a study in a high-transmission, ethni-
cally homogeneous endemic region of Bandiagara, Mali 
was carried out. This provides a potentially powerful per-
spective from which to study host immune responses. 
By using a case–control study design, with cases of 
severe malaria compared to controls of uncomplicated 
malaria, the transcriptional profiles of these divergent 




Children of both sexes aged between 6  months and 
5  years, residing in Bandiagara, Mali and presenting 
to the Bandiagara District Hospital with acute clinical 
malaria were eligible for enrolment. Prior to enrolment, 
informed consent was obtained from parents or legal 
guardians. Other eligibility criteria included meeting 
definitions of either uncomplicated or severe falciparum 
malaria and availability for the entire six-month study 
period. World Health Organization (WHO) criteria for 
uncomplicated and severe malaria were used [9]. The 
presence of either respiratory distress, anaemia (<15  % 
haematocrit or  <5  g/dL haemoglobin), hypoglycaemia 
(<40  mg/dL), persistent vomiting, or the inability to eat 
or drink necessitating parenteral feeding also qualified 
the patient as having severe malaria [9]. Exclusion crite-
ria included the presence of any disease with clinical fea-
tures similar to severe malaria (e.g., meningitis), a prior 
splenectomy or prolonged use of immunosuppressants, 
and any immunological intervention such as a vaccine or 
administration of immunoglobulins in the 6 months prior 
to enrolment in the study. Diagnoses were made during 
the August-December malaria transmission season.
Sample collection
Blood was collected from each study participant (2.5 mL) 
in a PAXgeneTM Blood RNA tube (PreAnalytix, Ger-
many) that stabilizes mRNA [17], and 20  µL was used 
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to prepare a Giemsa- stained blood smear to confirm P. 
falciparum infection. The PAXgeneTM tubes were kept 
at room temperature overnight in accordance with the 
manufacturer’s instructions (>2  h), then kept at −20  °C 
for 24 h and finally transferred to −80  °C for long-term 
storage. RNA was extracted in accordance with protocol 
using the PAXgeneTM Blood RNA kit. The quality of the 
RNA samples was evaluated with the use of Agilent RNA 
6000 nano kit (Agilent Technologies, Germany) and the 
corresponding Agilent 2100 Bioanalyzer, using the RNA 
integrity number (RIN) metric [18]. The A260/A280 ratio 
was also used to assess RNA purity. All microarray analy-
ses were carried out at the Malaria Research and Train-
ing Centre in Bamako, Mali. The Affymetrix Human 
Genome U133 Plus 2.0 GeneChip platform and protocols 
(Santa Clara, USA) were used for the expression analy-
sis. The Affymetrix GeneChip® Scanner 3000 was used 
to analyse the chips and Affymetrix GeneChip Operating 
Software version 1.2 (GCOS) was used to manage Affym-
etrix GeneChip data.
Microarray analysis
Data were analysed using R statistical software and the 
BioConductor ‘limma’ package [19]. Preprocessing and 
normalization were carried out using the robust multi-
array average (RMA) [20]. Quality control measures were 
assessed by analysing GAPDH-6 and actin ratios as they 
compare to scaling factors, as well as evaluating the RNA 
degradation patterns for the various chips. Hierarchi-
cal clustering analyses were performed to check for any 
probe co-regulation patterns [19]. In this pilot study rep-
resenting the first use of microarray technology in Mali, 
the use of Bonferroni or false discovery rate multiple-
testing adjustments was not appropriate for analysing 
this small dataset (Additional file  1: Figure S1). Instead 
the data were analysed using the criteria of greater than 
two-fold change [log2(2) = 1] and a significance level of 
p < 0.05 for testing the null hypothesis of whether the two 
sets are the same. To assess whether any specific biologi-
cal pathways were over- or under-expressed the probes 
matching the above criteria were filtered using the Kyoto 
Encyclopedia of Genes and Genomes [21] pathway filter 
in the statistical software R. The KEGG analyses were 
carried out for the probes matching these criteria sepa-
rately during the three time points of the study: acute ill-
ness, convalescence and late convalescence. The probes 
matching the criteria for the acute illness time point were 
also filtered using Ingenuity Pathway Analysis (Ingenuity 
Systems, Redwood City, CA, USA), and their expression 
was followed over the remaining two time points. Only 
the probes whose functions could be defined by Ingenu-
ity Pathway Analysis were included in this analysis.
qRT‑PCR analysis
Real-time PCR was carried out on samples from seven 
individuals (four severe cases, three uncomplicated con-
trols) for whom RNA remained after the microarray anal-
ysis (microarray analysis was carried out again on only 
those seven individuals for this comparison). Ten genes 
were analysed, eight matching the significance thresh-
old of greater than two-fold change [log2(2) = 1] and a p 
value of  <0.05 and two were housekeeping genes (beta-
actin and GAPDH). The selected genes were: CYP1B1, 
C1QB, CD163, CCR2, CLEC4D, NAIP, TLR2, and 
IL18R1. Pre-designed primer and probe sets for all genes 
were obtained from Applied Biosystems [22]. RT-PCR 
was carried out using the StepOnePlus™ Real-Time PCR 
System (Applied Biosystems), with TaqMan® reagents in 
accordance with the manufacturer’s recommendations. 
TaqMan® One-Step RT-PCR Master Mix Reagents Kit 
(PN 4304437) was used. Briefly, 50 ng of total RNA was 
used as a template for the one-step RT-PCR assay. The 
PCR conditions were as follows: 30 min at 48 °C, 15 s at 
95 °C, 1 min at 60 °C, 40 cycles. Data were analysed using 
ABI software to generate delta Ct values, and the delta 
Ct method was used with GAPDH as Ref. [23]. For each 
gene, at least one uncomplicated and one severe malaria 
patient had to have expression data for all of the tests 
done in triplicate to be included in the final analysis. For 
genes that had multiple probes in the Gene Chip, expres-
sion values were averaged for comparison with PCR 
data. The RT-PCR was carried out at Genomics/Affym-
etrix unit of the Malaria Research and Training Centre in 
Bamako, Mali.
Ethics approval
This study was approved by the ethics committee of the 
Faculty of Medicine, Pharmacy and Odonto-Stomatol-




Twenty-three uncomplicated malaria controls and 24 
severe cases (with cerebral and other severe symptoms) 
were enrolled in this study. Five severe cases with cerebral 
symptoms and five uncomplicated malaria controls were 
chosen for pilot microarray studies of gene expression on 
the day of presentation at the clinic (acute illness time 
point). Three each of controls and cases returned seven 
days later to submit blood samples for a gene expres-
sion analysis a week later (convalescence time point). The 
clinical characteristics of the acute illness and convales-
cence time point patients in the study are summarized in 
Table 1 (Additional file 2: Table S1).
Page 4 of 12Sobota et al. Malar J  (2016) 15:150 
Due to loss to follow-up and development of other 
disease between the relevant time points, eight different 
patients were followed to study the late convalescence, 
low transmission dry season gene expression following 
either severe cerebral (four patients) or uncomplicated 
(four patients) malarial disease. These patients were 
closely followed to assure that no other clinical episodes 
occurred between their acute illness time point presenta-
tion and their late convalescence follow-up. The clinical 
data for this group are summarized in Table 2 (Additional 
file 3: Table S2).
Top differentially expressed genes during acute illness
A total of 215 probes representing 134 genes were differ-
entially expressed between severe and uncomplicated cases 
and matched the inclusion criteria of  >twofold change 
and a p value  <0.05. The complete list of these probes is 
included in Additional file  4: Table S3. Furthermore, 37 
probes corresponding to 33 genes showed differential 
expression at a p value <0.005 and a greater than twofold 
change (Table 3), and four probes, representing MB21D1, 
SAMSN1, PLBD1, and MKRN1 genes, had a p value <0.001. 
These top four genes have not been previously associated 
with malaria pathogenesis and/or severity. Of the remain-
ing probes, four were in three genes, HSPA6, TLR8 and 
FOS, previously identified in experiments for malaria 
severity in human or murine systems [24–26]. Two probes 
interrogated the expression of the HSPA6 gene (p values 
of 0.0020 and 0.0040), with single association in TLR8 and 
FOS (p values of 0.0038 and 0.0037, respectively) (Table 3).
KEGG pathway analysis of the acute illness time point 
samples
A KEGG analysis based on the 215 significant probes 
showed that the malaria pathway had the second-highest 
odds ratio (Table  4). A hierarchical clustering heat map 
Table 1 Clinical characteristics of patients enrolled for the acute illness and convalescence time points
All patients were febrile and parasitaemic for P. falciparum at the acute time point and all were afebrile and aparasitaemic at the convalescent time point except 
uncomplicated control patient 4 (data not available)
Patient Gender Age (years) Symptoms during acute illness Symptoms in convalescence
Severe malaria cases
 2 Male 3 Convulsions None
 4 Male 4 Obtundation None
 6 Female 3 Prostration, lethargy None
 9 Male 2 Coma, convulsions None
 12 Female 3.5 Prostration, lethargy None
Uncomplicated malaria controls
 1 Female 5 Diarrhoea Cough
 3 Female 1.5 Cough Cough
 4 Male 4 Headache, chills, vomiting –
 7 Male 3 Chills None
 12 Female 3 Headache, abdominal pain, cough Lethargy, abdominal pain
Table 2 Clinical characteristics of patients enrolled for the late convalescence time point
All patients were febrile and parasitaemic for P. falciparum during the acute illness (except severe malaria case 10, axillary T = 36.8 °C) and all patients were afebrile 
and aparasitaemic at late convalescence (except uncomplicated malaria control patient 2, axillary T = 37.7 °C)
Patient Gender Age (years) Symptoms during acute illness Symptoms in late convalescence Time since acute illness (days)
Severe malaria cases
 8 Female 2 Convulsions None 165
 10 Male 4 Prostration/lethargy None 162
 17 Female 3 Prostration/lethargy None 147
 18 Female 4 Obtundation None 145
Uncomplicated malaria controls
 2 Male 3 Diarrhoea, vomiting None 154
 6 Male 3 Diarrhoea, vomiting None 153
 14 Male 2 Vomiting None 137
 23 Female 5 Headache None 134
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demonstrates the co-regulation of the 215 significant probes 
(Fig.  1a), and reveals the degree of separation between 
severe cases and uncomplicated ones. The odds ratios for 
the three top pathways, Staphylococcus aureus infection, 
malaria, and leishmaniasis were 15.2, 11.8 and 10.3, respec-
tively, and all had p values of less than 0.001. Five of the 86 
probed genes in the malaria pathway showed differential 
expression between the severe and uncomplicated case 
groups, with the expected value of 1. Both toll-like receptors 
two and four (TLR2, TLR4), part of the KEGG malaria 
pathway, had higher expression in the severe cases com-
pared to the uncomplicated malaria group (2.07-fold higher 
for TLR2, 2.27- and 2.46-fold higher for the TLR4 probes). 
The other three significant genes associated with malaria in 
KEGG were the Complement Receptor 1 (2.05-fold higher 
expression in severe cases) along with glycophorin A and B 
(2.89- and 2.88-fold higher uncomplicated case expression, 
respectively). Since Staphylococcus aureus infection and 
Table 3 Significant genes differentiating between severe and uncomplicated malaria at the acute illness (function desig-
nated by Ingenuity Pathway Analysis)
Gene Probe Description Acute illness log (fold change) p value
MB21D1 1559051_s_at Mab-21 domain containing 1 −1.482461 3.64E−04
SAMSN1 1555638_a_at SAM domain, SH3 domain and nuclear localization signals 1 −1.265117 4.52E−04
PLBD1 218454_at Phospholipase B domain containing 1 −1.016165 6.47E−04
MKRN1 209845_at Makorin ring finger protein 1 1.078957 9.25E−04
PSMF1 201053_s_at Proteasome (prosome, macropain) inhibitor subunit 1 (PI31) 1.088499 1.40E−03
HEMGN 223670_s_at Haemogen 1.782966 1.41E−03
KREMEN1 227250_at Kringle containing transmembrane protein 1 −1.004677 1.47E−03
FPR2 210772_at Formyl peptide receptor 2 −1.121253 1.56E−03
BCL6 215990_s_at B cell CLL/lymphoma 6 −1.244554 1.71E−03
HSPA6 117_at Heat shock 70 kDa protein 6 (HSP70B’) −1.358852 2.02E−03
CCR2 207794_at Chemokine (C–C motif ) receptor 2 −1.041326 2.11E−03
FPR2 210773_s_at Formyl peptide receptor 2 −1.227297 2.23E−03
WNK1 1555068_at WNK lysine deficient protein kinase 1 1.507248 2.25E−03
HLA-DPA1 211990_at Major histocompatibility complex, class II, DP alpha 1 −1.370427 2.40E−03
SOS1 212777_at Son of sevenless homologue 1 (Drosophila) −1.564278 2.41E−03
SAMSN1 220330_s_at SAM domain, SH3 domain and nuclear localization signals 1 −1.184775 2.47E−03
GNLY 205495_s_at Granulysin −1.246373 2.66E−03
TMEM165 226825_s_at Transmembrane protein 165 −1.055969 2.72E−03
EIF5A 201123_s_at Eukaryotic translation initiation factor 5A 2.023113 2.80E−03
CCR2 206978_at Chemokine (C–C motif ) receptor 2 −1.346736 2.94E−03
C14orf45 220173_at Chromosome 14 open reading frame 45 1.49005 3.20E−03
ITGAM 205786_s_at integrin, alpha M (complement component 3 receptor 3 sub-unit) −1.038506 3.30E−03
BPGM 203502_at 2,3-bisphosphoglycerate mutase 1.360559 3.34E−03
FECH 203116_s_at Ferrochelatase 1.547674 3.42E−03
IRAK3 213817_at Interleukin-1 receptor-associated kinase 3 −1.445589 3.52E−03
DUSP1 201041_s_at Dual specificity phosphatase 1 −1.168216 3.64E−03
FOS 209189_at FBJ murine osteosarcoma viral oncogene homolog −1.062789 3.69E−03
TLR8 220832_at Toll-like receptor 8 −1.131984 3.80E−03
FOSL2 228188_at FOS-like antigen 2 −1.020796 3.89E−03
SRRD 213608_s_at SRR1 domain containing 1.110322 3.90E−03
NLRC4 1552553_a_at NLR family, CARD domain containing 4 −1.001566 3.91E−03
HSPA6 213418_at Heat shock 70 kDa protein 6 (HSP70B’) −1.327448 3.98E−03
PSMF1 201052_s_at Proteasome (prosome, macropain) inhibitor subunit 1 (PI31) 1.021332 4.11E−03
MS4A6A 219666_at Membrane-spanning 4-domains, subfamily A, member 6A −1.031532 4.29E−03
DUSP3 201537_s_at Dual specificity phosphatase 3 −1.024139 4.36E−03
EGLN1 224314_s_at Egl nine homologue 1 (Caenorhabditis elegans) −1.036334 4.37E−03
STEAP4 1556185_a_at STEAP family member 4 −1.385834 4.86E−03
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Table 4 Top KEGG pathways differentially expressing between severe cases and uncomplicated controls during acute ill-
ness
a  Expected count, the number of genes in the pathway that would be expected to be differentially expressed by chance
b  Observed count, the number of genes in the pathway observed to be differentially expressed
KEGG pathway No. genes Expected counta Observed countb Odds ratio p value
Staphylococcus aureus infection 47 1 6 15.197 <0.001
Leishmaniasis 66 1 6 10.342 <0.001
Malaria 48 1 5 11.807 <0.001
Systemic lupus erythematosus 104 1 5 5.067 0.005
Allograft rejection 33 0 3 9.758 0.005
Complement and coagulation cascades 66 1 4 6.386 0.005
Graft-versus-host disease 35 0 3 9.145 0.006
Type I diabetes mellitus 39 0 3 8.122 0.008
Toxoplasmosis 121 1 5 4.308 0.009
Rheumatoid arthritis 79 1 4 5.264 0.01
Cytokine-cytokine receptor interaction 234 3 7 3.145 0.011
Hematopoietic cell lineage 83 1 4 4.993 0.011
Auto-immune thyroid disease 47 1 3 6.634 0.013
Chagas disease 98 1 4 4.183 0.02
Chemokine signaling pathway 165 2 5 3.094 0.03
Asthma 26 0 2 7.976 0.031
Antigen processing and presentation 67 1 3 4.541 0.034
Cell adhesion molecules (CAMs) 119 1 4 3.404 0.038
Renal cell carcinoma 70 1 3 4.335 0.038
MAPK signaling pathway 248 3 6 2.464 0.047
Fig. 1 Hierarchical clustering of arrays using Pearson’s correlations on probes with a fold change greater than two and a p value <0.05. Down- 
regulated probes are in green, up-regulated probes are in red. a Heat map for the 215 probes matching the criteria for the acute illness patients;  
b Heat map for the 362 probes matching the criteria for the convalescence patients; c Heat map for the 340 probes matching the criteria for the dry 
season time point
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leishmaniasis are infectious diseases, and each had a similar 
odds ratio to malaria, the top three pathways were assessed 
for any overlap in significant probes. The leishmaniasis 
pathway had three probes in common with malaria (TLR2, 
TLR4, CR1), while Staphylococcus aureus infection had one 
(CR1). Other significant KEGG pathways of relevance to 
malaria pathogenesis included complement and coagulation 
cascades and antigen processing and presentation with odds 
ratios of 6.4 and 4.5, respectively.
KEGG pathway analyses of the convalescence and late 
convalescence time point samples
Analyses of differentially expressed KEGG pathways dur-
ing convalescence revealed that the ‘malaria’ pathway 
was no longer significant at the  <0.05 level when com-
paring uncomplicated versus severe patients (Additional 
file  5: TableS4). KEGG assessment of expression differ-
ences in the two groups at the late convalescence time 
point showed that the malaria pathway was again statisti-
cally significant (Additional file 6: Table S5). Hierarchical 
clustering heat maps were created for both the convales-
cence (Fig.  1b) and the late convalescence (Fig.  1c) time 
points, and the separation of severe from uncomplicated 
cases observed during acute illness was maintained. For 
the three severe and three uncomplicated case patients 
followed from acute disease to convalescence, the list of 
KEGG pathways differentiated at the 0.05 level includes 
the antigen processing and presentation pathway. Dur-
ing acute illness, this pathway had an odds ratio of 4.5 
and a p value of 0.034, and it is still significant at conva-
lescence seven days later with an odds ratio of 8.5 and a p 
value of 0.002 (Additional file 5: Table S4). With only one 
gene expected to show significance at the given threshold, 
HLA-DQA1 (3.97-fold higher expression in severe cases), 
HLA-DQB1 (10.34-fold higher expression in severe cases), 
HLA-DPA1 (2.01-fold higher expression in uncomplicated 
cases), and KLRC3 (3.39-fold higher expression in severe 
cases) all matched the above stated criteria. The unrelated 
cases and controls from the low transmission, late con-
valescence time point list malaria as the 12th most sig-
nificantly differentiated pathway with an odds ratio of 4.1 
and a p value of 0.043 (Additional file 6: Table S5). Three 
genes were observed to be expressed above the predefined 
threshold, CD36 (4.38- and 3.81-fold higher expression 
in the uncomplicated cases for two probes), IL18R (2.30-
fold higher expression in uncomplicated cases) and TLR4 
(2.94- and 2.61-fold higher expression in uncomplicated 
cases), where only one was expected.
Ingenuity pathway analysis of the acute illness time point 
samples
The top canonical pathways produced by applying Inge-
nuity Pathway Analysis to significant probes at acute 
illness were the complement system, toll-like recep-
tor signaling and role of pattern recognition receptors 
in recognition of bacteria and viruses. Figure  2 shows 
a stacked bar chart of these pathways and other signifi-
cant pathways considered to be relevant to the patho-
genesis of malaria: Cytotoxic T lymphocyte-mediated 
apoptosis of target cells (11th ranked pathway in terms 
of significance), dendritic cell maturation (13th), T cell 
receptor signaling (14th), T helper cell differentiation 
(18th), and IL-10 signaling (20th) [27]. Of the significant 
probes that overlap with the above listed canonical path-
ways, the great majority shows lower expression in the 
patients who developed uncomplicated disease as com-
pared to those who had severe symptoms. Differentially 
expressed probes form these canonical pathways that 
were previously shown to play a role in severe malaria 
pathogenesis were TLR2, TLR4, TLR8, HSPA6, CR1, 
C1qA, C1qB, C1qC, FOS, and GZMB. The TLR probes 
showed a higher expression in severe malaria cases dur-
ing acute illness (2.07-fold for TLR2, 2.19-fold for TLR8, 
2.27 and 2.46-fold for the TLR4 probes). HSPA6 levels 
were also higher in severe cases by 2.56-fold during this 
time point, as was CR1, which was expressed at a higher 
level in severe cases by 2.04. C1q is comprised of three 
chains, all of which were found to be expressed at higher 
levels in the severe patients (C1qA by 2.79-fold, C1qB by 
3.12-fold and C1qC by 2.64-fold). The FOS and GZMB 
genes were also found to be expressed at elevated levels 
in severe malaria cases in this study (by 2.09- and 2.31-
fold, respectively).
Expression of genes involved in acute illness phenotype 
differentiation during convalescence and late 
convalescence
Longitudinal expression dynamics of the probes relevant 
to severe versus uncomplicated malaria presentation at 
acute illness from the section above were evaluated dur-
ing convalescence. Eleven probes corresponding to eight 
genes were analysed; these genes were previously found 
to be experimentally relevant in severe malaria. Figure 3 
displays the evolution of the expression of these genes 
over the three time points of this study. Seven of the eight 
genes showed characteristics that make them reasonable 
targets as molecular markers of severe malaria.
TLR probes showed a higher expression in severe 
malaria cases during acute illness (2.07-fold for TLR2, 
2.19-fold for TLR8, 2.27 and 2.46-fold for TLR4 probes). 
By convalescence, most of the probes still showed higher 
expression in severe cases, but by a smaller margin (1.03-
fold for TLR2, 1.85- and 1.33-fold for the TLR4 probes), 
with the exception of the TLR8 probe which showed a 
higher expression in the uncomplicated cases (1.36-fold). 
This trend continued into late convalescence, where all 
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probes showed higher expression in uncomplicated cases 
as compared to severe (1.94-fold for TLR2, 1.73-fold for 
TLR8, 2.61- and 2.94-fold for the TLR4 probes). HSPA6 
levels were higher in severe cases by 2.56-fold during the 
acute illness time point, by convalescence uncomplicated 
cases were 1.17-fold higher and in late convalescence 
uncomplicated cases were expressed 1.90 times higher. 
During acute illness, CR1 was expressed at a higher level 
in severe cases by 2.04, 7  days later during convales-
cence it was 1.09 times higher is severe cases, and by late 
Fig. 2 Stacked bar chart displaying the top canonical pathways found to be differentially represented in comparing gene expression in uncompli-
cated controls to severe cases during acute illness. Total number of genes in each pathway is displayed above each bar, in bold. Pathways are ranked 
by statistical significance. Only those considered pertinent to the malaria phenotype are displayed: Complement system (highest statistical signifi-
cance), toll-like receptor signalling (2nd), role of pattern recognition receptors in recognition of bacteria and viruses (3rd), cytotoxic T lymphocyte-
mediated apoptosis of target cells (11th), dendritic cell maturation (13th), T cell receptor signalling (14th), T helper cell differentiation (18th) and 
IL-10 signalling (20th) [27]
Fig. 3 Longitudinal expression of molecular markers. Uncomplicated to severe expression ratios of eight severe malaria candidate markers at the 
acute illness time point, convalescence and late convalescence. Average expression values were used for the two significant TLR4 probes and 
separately C1Q sub-units A, B, and C
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convalescence CR1 was expressed at higher levels in the 
uncomplicated case patients by 1.50-fold. FOS expres-
sion was higher in severe cases during acute illness as 
well as during convalescence, by 2.08 and 1.11, respec-
tively, but by late convalescence, the uncomplicated cases 
that showed a 1.90-fold higher expression. GZMB had a 
2.33-fold higher expression in severe cases during acute 
illness, 2.04-fold higher expression in severe cases during 
convalescence, but by the late convalescence time point 
uncomplicated cases expressed the gene 1.66-fold higher.
C1q was the only protein out of the eight candidates 
that did not follow a similar expression profile. Three 
probes corresponding to the chains of the C1q protein 
show a change from having higher expression in the 
severe patients during acute illness (C1qA by 2.79-fold, 
C1qB by 3.12-fold, C1qC by 2.64-fold) to showing higher 
expression in uncomplicated cases during convalescence 
(C1qA by 1.65-fold, C1qB by 1.54-fold, C1qC by 1.69-
fold). By the late convalescence time point, the difference 
in these probes between uncomplicated and severe cases 
was seemingly indistinguishable between the groups 
(C1qA 1.10-fold higher expression in severe, C1qB no 
difference, C1qC 1.20-fold higher expression in severe).
qRT‑PCR validation
The Spearman Rho for the correlation of the GeneChip 
and RT-PCR expression was 0.87. The Pearson’s correla-
tion between the GeneChip expression data and RT-PCR 
values was 0.72, but there were not enough observations 
to assure a normal distribution (Additional file  7: Table 
S6). The correlations indicate consistency between the 
two approaches considering the low fold change inclu-
sion criteria for the expression data.
Discussion
Seven molecular marker candidate genes of severe 
malaria were identified in this study. Evaluating the base-
line expression of these genes may identify individuals at 
risk prior to infection. When comparing gene expression 
between uncomplicated and severe malaria patients at 
acute illness, the list of differentially expressed genes was 
enriched for those consistently associated with malaria 
in prior studies. Previous studies reported differences 
in expression of toll-like receptors and the complement 
system in healthy as compared to uncomplicated P. fal-
ciparum malaria [7, 27, 28]. This study demonstrated 
that TLR and complement systems are not just impli-
cated in human gene expression in response to uncom-
plicated symptoms of a P. falciparum infection, but also 
appear to play a role in the pathophysiology of severe cer-
ebral malaria. These genes were expressed at significantly 
higher levels in patients presenting with severe symp-
toms during acute illness. All of the sub-units of C1q 
were elevated in severe cases, as was CR1, TLR2, TLR4, 
and TLR8. These results are consistent with prior studies 
showing dysregulation of innate immunity and inflam-
matory mechanisms in severe malaria morbidity [23, 25, 
27, 28].
The relevance of both complement and TLR pathways 
is well established in response to malaria. The classi-
cal pathway of complement activation occurs via bind-
ing of antibodies in immune complexes initiated by C1q 
[29]. CR1 has been shown to be protective against P. 
falciparum infections in low concentrations, but when 
over-expressed it can lead to rosetting of blood cells and 
subsequent severe malaria [8, 28, 29]. Single nucleotide 
polymorphisms (SNPs) in CR1 also associate with disease 
manifestation in India [28]. The elevation of TLR probes 
in severe patients in this study also recapitulates previ-
ous findings [29]. TLR4 has been associated with clinical 
malaria outcomes in human studies as its suppression in 
dendritic cells has been associated with uncomplicated 
P. falciparum infection in Malian children of the Dogon 
ethnicity [30]. TLR8 is thought to prime and potenti-
ate the inflammatory response to pathogens, thereby 
contributing to the pathogenesis of severe malaria [25]. 
HSPA6 expression has also been previously implicated 
in malaria pathogenesis, although it has never been con-
sidered when studying the severe versus uncomplicated 
phenotype. Upon P. falciparum infection of nucleated 
erythroid precursor cells, the orthochromatic cells, the 
level of HSPA6 was shown to be significantly increased 
above what it was in controls [24].
This study also replicates in human P. falciparum 
malaria findings from mouse models for severe ver-
sus uncomplicated Plasmodium berghei malaria, which 
implicated genes involved in both complement and TLR, 
along with FOS and GZMB [26]. In a murine model, 
a TLR 2/4 −/− genotype leads to increased resistance 
against developing experimentally induced P. berghei 
cerebral malaria [31]. The c-fos protein was found to be 
expressed at elevated levels in experimental murine P. 
berghei-induced cerebral malaria [26]. While the c-fos 
protein was also found to be slightly elevated in non-
cerebral murine malaria cases, its level and extent of 
neurological involvement was far greater in the cerebral 
cases. This is the first study directly linking FOS expres-
sion levels to severe malaria in humans. Another mouse 
model found the GZMB−/− genotype to be protective of 
P. berghei cerebral malaria [32].
The use of three time points throughout the evolution 
of disease permitted study of the changes in expression 
as disease progressed from the acute illness episode, 
through convalescence and into the late convalescence, 
low transmission season. Although the patient popula-
tion is not the same for the acute and late convalescence 
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time points, the results from the late convalescence 
time point can stand alone, as these are children who 
experienced severe versus uncomplicated malaria in 
the previous rainy season; therefore, differences in gene 
expression from this time point have a prognostic value. 
While the various C1Q probes appeared to have simi-
lar expression patterns, the TLR probes, GZMB, FOS, 
HSPA6, and CR1 were all expressed at higher levels in 
the uncomplicated cases during the late convalescence, 
dry season time point. The higher expression of the TLR 
genes, GZMB, FOS, HSPA6, and CR1, in uncomplicated 
malaria cases during the late convalescence time point 
can be interpreted two ways. It is possible that pro-
longed suppression of these genes following severe infec-
tion is causal. Considering that the average time elapsed 
since the acute illness presentation was 150  days, and 
no intermittent malaria episodes occurred, this scenario 
is unlikely; although it cannot be ruled out. Obtaining 
baseline expression levels, prior to the development of 
malaria, would have been more informative, however 
there are substantial logistical obstacles on account of the 
relatively low prevalence of cerebral malaria. It can also 
be argued that the late convalescence levels represent the 
baseline expression values for these individuals. Under 
this hypothesis, the baseline expression levels of these 
genes are candidate markers for developing severe malar-
ial disease upon infection.
The WHO definition of severe malaria allows for a 
broad spectrum of clinical symptoms, ranging from res-
piratory distress to cerebral complications, amongst 
others [9]. While this is a clinically convenient method 
of clustering individuals and rationing appropriate care, 
it is problematic from the perspective of gene expres-
sion profiling, in that each clinical scenario of severe 
malaria spectrum may have a different underlying gene 
expression profile. All patients defined as severe cases 
at all time points of this study were classified based on 
cerebral complications; however, there is some hetero-
geneity even within this group (Tables 1, 2). Considering 
the broad spectrum of clinical features that fall into the 
severe malaria category, having all of the patients fall into 
the cerebral complications phenotype is a strength of this 
study.
In an experiment looking strictly into host gene expres-
sion, the differences in P. falciparum genetics and their 
interaction with host factors are a possible source of 
error [7]. The importance of parasite genetics in deter-
mining the clinical trajectory of disease has been dem-
onstrated in previous studies delineating the effects 
of var gene expression in governing clinical outcomes 
[33–35]. Larger studies are needed to examine parasite 
genetic polymorphism and gene expression differences 
in relation to human gene expression and clinical malaria 
syndromes. Host circadian rhythm expression differences 
could have also added to the variation between the severe 
and uncomplicated cases of malaria as exact blood col-
lection times were not measured, therefore, cases and 
controls could not be matched on this basis. It is also 
possible that the findings are confounded by variable 
white cell counts in the patient population; however, the 
capacity to separate the cells was not yet available in Mali 
during this pilot study. Furthermore, since the objective 
was to find easily tested molecular markers, whole blood 
analyses were implemented.
The availability and increasing affordability of genome-
wide expression arrays has intensified the search of 
human molecular markers for susceptibility to severe 
malaria. The low incidence of severe malaria limits the 
potential for genome-wide approaches from a sequenc-
ing/genome-wide association perspective because of the 
sample size necessary to attain significance in such stud-
ies. The presence of various sub-types of severe malaria 
further complicates such studies due to phenotyping 
considerations, again lowering the potential sample size 
for a well-designed study. The uncomplicated malaria 
phenotype has been shown to be problematic in genome-
wide association studies (GWAS), where HBS did not 
attain genome-wide significance in the initial screen [13]. 
Expression approaches such as the one described here 
might provide a better solution to unravelling severe 
malaria pathogenesis. Expression studies are more pow-
ered for finding relevant genes because they only carry 
out 22,000 independent tests, as opposed to the >1 mil-
lion in GWAS, and gene expression is closer to the clini-
cal phenotype than sequence variation. This is supported 
by the results of this study, as they were highly enriched 
for genes consistently associated with the phenotype in 
prior experiments, despite the small sample size. The 
results verify expression findings previously limited to 
the mouse model organism, or human data only previ-
ously associated with uncomplicated disease. The gene 
clusters highlighted by this study can guide future inquir-
ies into unravelling the intricacies of the protective host 
immune response against severe malarial infection. 
Understanding the genetics of the host response, via gene 
expression, may accelerate the identification of clinically 
useful prognostic indicators, and ultimately, inform treat-
ment and prevention guidelines for severe malaria.
Conclusions
This study suggests that overexpression of genes previ-
ously associated with uncomplicated malaria may also 
be associated with severe disease. Here, models of severe 
malaria were replicated in humans for the first time, and 
genes previously thought only to contribute to uncom-
plicated malaria were implicated in severe disease. In 
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particular, genes in the complement and toll-like recep-
tor pathways were expressed at higher levels in severe 
cases during acute illness. The longitudinal component 
of this study demonstrated that 7  days after presenta-
tion and treatment, the levels of these complement and 
toll-like receptor genes were indistinguishable in the 
uncomplicated and severe malaria patients. However, 
when expression of these genes was evaluated during the 
dry season following acute illness, patients with previous 
severe malaria showed lower levels of expression in these 
genes. These low baseline values should be evaluated as 
possible candidate biomarkers for severe malaria.
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